CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Identification by PCR of the SARS-COV-2 virus in samples taken from the fetusWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug941 FilmArray PCR on respiratory samples Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D011014 Pneumonia NIH 0.06
D007239 Infection NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID

Maternal-fetal transmission in the second or third trimester of pregnancy of the SARS-COV-2 virus could explain some late fetal losses. Finding a cause in the context of fetal loss is essential for parents and caregivers. It helps to understand the history of the disease, to address the possible risk of a recurrence and to plan for future pregnancies. If the maternal-fetal transmission of COVID 19 is confirmed and that it is responsible for obstetric complications, a preventive action could be proposed to the patients by the preconception vaccination. The investigators are seeking to clarify the frequency of this transmission is information awaited by caregivers, women, couples in particular when the latter are in distress from late fetal loss.

NCT04387253 Identification of the Mother or Fetus Contamination by SARS Cov-2 Research the Presence of Viruses at Different Sites of the Mother and the Fetus or Father The Survey Builds on a Network Work Already Organized Around the CPDPN of Poitou-Charentes Analysis Laboratories of the Poitiers CHU Diagnostic Test: Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus

Primary Outcomes

Description: Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus

Measure: Estimate the prevalence of SARS-CoV-2 infection in women with late fetal loss of unexplained cause.

Time: 2 months


No related HPO nodes (Using clinical trials)